key: cord-0741428-ilnrvbpa
authors: Mannucci, Edoardo; Nreu, Besmir; Monami, Matteo
title: Factors associated with increased all-cause mortality during the COVID-19 pandemic in Italy
date: 2020-06-26
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.06.077
sha: 55cd6faa1fbe1aa2345a6c045684f5faa2ad6686
doc_id: 741428
cord_uid: ilnrvbpa

Abstract Background The number of excess deaths in February-March 2020 in Italy, in comparison to the previous years, was considerably higher than recorded COVID19-related deaths. The present study is aimed at exploring the associations of excess mortality with some indices related to the epidemic and its management. Methods Data on all-cause mortality from February 20th to March 31st, in years from 2015 to 2020, and demographic, socioeconomic and healthcare organization data of each Italian region were obtained from Italian Institute of Statistics. Non-COVID19-Imputed Excess Mortality (NCIEM) was calculated as the difference between excess 2020 mortality and reported COVID19 mortality. The association of NCIEM with the rate of COVID-19 cases, COVID-19 mortality, and other potential moderators was assessed using linear regression models. Results The nationwide number of excess deaths, COVID-19 deaths was 26,701 and 13,710, respectively, with a difference of 12,991. NCIEM in different Regions showed a direct correlation with COVID-19 mortality (r2 = 0.61, p < 0.001) and total cases (r2 = 0.30, p = 0.012), and an inverse correlation with cases/total tests ratio (r2 = 0.49, p = 0.001). Direct correlations were also found with the proportion of institutionalized elderly, whereas inverse correlations were observed with prevalence of diabetes, cardiovascular mortality, and density of general practitioners. Conclusions The impact of the COVID19 epidemic on all-cause mortality is considerably greater than that indicated by official counts of victims. Limited testing capacity and causes of death other than COVID19 could contribute to the increase in overall mortality rates.

Italy was the European epicenter of the COronaVIrus Disease 19 (COVID-19) pandemic, with the highest number of recorded cases and deaths during at the end of March 2020 (1). In some areas of the Country, and most notably in the Lombardia region, the capacity of hospital care, and particularly of intensive care units, was overwhelmed, possibly contributing to a very high COVID-19-related mortality rate (2) . The Italian Health Ministry (3) daily reports the number of cases of COVID19 and deaths in COVID19 patients, confirmed with microbiological testing (PCR-detected viral mRNA from pharyngeal swabs). Such reports could considerably underestimate the actual epidemic, due to the relatively high proportion of asymptomatic or oligosymptomatic cases (4). In addition, limited laboratory capacity could have prevented microbiological testing even in symptomatic cases. Anecdotical reports suggested that some patients died of COVID19 at home, without receiving a confirmed diagnosis, and without being included in the official count of COVID19-related deaths (5) . In some municipalities of the Province of Bergamo, Lombardia, the number of excess deaths at the Registry Office in March 2020, in comparison to the same months of previous years, was considerably higher than recorded COVID19-related deaths (3). In order to provide some information on the impact of the epidemic on mortality, the Istituto Italiano di Statistica (ISTAT) collected mortality data for the period February 20 th -March 31 st , 2020, from Registry Office of 6,866 municipalities (out of a total of 7,094) throughout Italy. These data, which do not provide any information on the actual cause of death, showed an increase of 27.9% (4).

The present study is aimed at exploring the associations of excess mortality with some indices related to the epidemic and its management, in order to obtain some insight on possible underlying mechanisms.

Data on all-cause mortality from February 20 th to March 31 st , in years from 2015 to 2020, were obtained from ISTAT (4). Those data include a sample of 6,866 (out of a total of 7,904) Italian municipalities, accounting for a population of 52,452,445 (out of a total population of 60,359,546).

We retrieved daily data on cases of COVID19, deaths for COVID19 (i.e., deaths in individuals with positive test results), and total number of diagnostic tests performed up to March 31 st , 2020, in each Region, from the Health Ministry website (3). Municipalities included in the ISTAT survey were considered representative of their Regions, in order to estimate total regional mortality.

Excess 2020 mortality was defined as the difference between mean 2015-2019 and 2020 mortality rates for the reference period. Non-COVID19-Imputed Excess Mortality (NCIEM) was calculated as the difference between excess 2020 mortality and reported COVID19 mortality.

The ratio of cases/total tests performed was calculated for each Region, as an index of aggressiveness of local policies with respect to case finding.

Demographic, socioeconomic and healthcare organization data of each region were retrieved from ISTAT (6). The association of NCIEM with the rate of COVID-19 cases, COVID-19 mortality, and the other potential moderators listed above, in different Regions was assessed using linear regression models, weighed for total population. Multivariate analyses were also performed with each moderator, adjusting for COVID-19 mortality. Analyses were performed on SPSS (SPSS-Inc., Chicago, IL, USA) 25.0.

This work is based on publicly available data, needing no ethical approval.

Based on ISTAT data (4), mortality from 20 th , February and 31 st , March 2020 was higher than the 2015-2019 average in all Regions (Table 1) r 2 = 0.61, p<0.001) and total cases (r 2 =0.30, p=0.012), and an inverse correlation with cases/total tests ratio (r 2 =0.49, p=0.001). Significant direct correlations were also found with mean personal income and proportion of elderly in nursing homes, whereas inverse correlations were observed with prevalence of diabetes, 2019 cardiovascular mortality, and density of general practitioners (Table 2 ). In alternative multivariate analyses, after adjusting for COVID-19 mortality, only prevalence of diabetes retained a statistically significant association with NCIEM (Table 2 ).

Data from the ISTAT survey show that the COVID19 epidemic is associated with a relevant increase in all-cause mortality rates (4). This phenomenon has also been observed in other European

Countries with major COVID19 outbreaks, such as Spain, UK, France, Belgium, Netherlands, and Sweden (7) . Notably, the number of observed deaths is higher than the sum of average deaths in J o u r n a l P r e -p r o o f previous years and reported COVID19-related deaths, meaning that a fraction of excess mortality in 2020 is not explained by official COVID19 deaths. Excess mortality in European countries participating to the EUROMomo network (7) is higher than reported COVID19 mortality (8), although the difference between the two figures does not appear to be so wide as that recorded in Italy.

Considerations on causes underlying this unexplained excess mortality are necessarily speculative, since data on causes of death are unavailable from Registry Office-based reports. A part of COVID19 patients could have died at home or in nursing homes without having received a microbiological diagnosis, thus escaping official records of COVID19 victims. At the peak of the epidemic, in the second half of March, in several areas of Lombardia and neighboring Regions, resources of the healthcare system were insufficient for extensive testing of outpatients. In fact, NCIEM appears to be higher in Regions with a higher number of recorded COVID19 cases and deaths. In addition, the cases/total tests ratio, which we assumed as an index of testing capacity, was significantly associated with NCIEM, even though statistical significance was lost after adjusting for recorded COVID19-related mortality. Notably, NCIEM was higher in Regions with a greater proportion of elderly residents of nursing homes, who could have had a lower chance of being properly tested.

The lower NCIEM rates in Regions with a higher density of GPs points to the relevance of healthcare organization: a stronger territorial network of healthcare professionals could be more efficient in testing and tracing potential COVID19 cases, thus reducing underdiagnosis.

The association of higher diabetes prevalence with lower NCIEM rate is more difficult to explain.

Diabetes has been associated with worse outcomes of COVID-19 (9); since this notion was well known to the medical community, it can be speculated that patients with diabetes and symptoms suggestive of COVID-19 were tested more accurately. It is also possible that the inverse association of diabetes prevalence and NCIEM is spurious, being determined by unavailable confounders. Available information on mortality during the epidemic of COVID19 is still incomplete. The municipalities included in the ISTAT report (4) are not necessarily representative of their Regions, as assumed for the present analysis; on the other hand, the Ministry Health does not provide data on recorded COVID-19 deaths split by municipality, but only by Region. As a consequence, the estimates reported here are intended as preliminary.

Despite these limitations, available data show that the impact of the COVID19 epidemic on all-cause mortality is considerably greater than that indicated by official counts of victims. Mechanisms underlying this unexplained excess mortality, which could include causes different from COVID19, deserve further, specific investigation. Many fatal cases of COVID19 remain undiagnosed because of limited testing capacity; causes of death other than COVID19 could contribute to the increase in overall mortality rates.

Dr Monami reports personal fees from Astra Zeneca, personal fees from Boehringer-Ingelheim, personal fees from Eli-Lilly, personal fees from Novo Nordisk, personal fees from Sanofi, and J o u r n a l P r e -p r o o f personal fees from Takeda outside the submitted work; Dr. Nreu Besmir is an employer of Novo Nordisk; Dr Mannucci reports grants and personal fees from AstraZeneca, personal fees from Abbott, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Eli Lilly, grants from Genentech, grants from Molteni, personal fees from Merck, grants and personal fees from Novo Nordisk, and personal fees from Sanofi outside the submitted work. inhab.: inhabitants. 

COVID-19 and Italy: what next? Lancet

Suppression of COVID-19 outbreak in the municipality of

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and metaregression